Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
Stopped early · Not applicable
Conditions studied: Lung Cancer
In brief
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so it can be removed. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients who are undergoing surgery for stage I, stage II, or stage III non-small cell lung cancer.
Key facts
- Study ID
- NCT00104728
- Run by
- H. Lee Moffitt Cancer Center and Research Institute
- People needed
- 42
- Starts
- 2004-10-01
- Expected to finish
- 2009-03-01
- Last updated by the study team
- 2012-10-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.